United Therapeutics Corporation Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
United Therapeutics Corporation (UTHR) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $56.19 million for the 12-month period ending 2011-12-31, per its 10-K filed 2013-02-26.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2013-02-26
- United Therapeutics Corporation adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2011 was $56.19M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2011-12-31 | $56.19M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |